A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD
Wilfried De Backer,1 Jan De Backer,2 Wim Vos,3 Ilse Verlinden,3 Cedric Van Holsbeke,3 Johan Clukers,1 Bita Hajian,1 Shahid Siddiqui,4 Martin Jenkins,5 Colin Reisner,4,6 Ubaldo J Martin4 1Department of Respiratory Medicine, University of Antwerp, Antwerp, Belgium; 2FLUIDDA, Los Angeles, CA,...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-08-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-randomized-study-using-functional-respiratory-imaging-to-characteriz-peer-reviewed-article-COPD |
| _version_ | 1818847712729104384 |
|---|---|
| author | De Backer W De Backer J Vos W Verlinden I Van Holsbeke C Clukers J Hajian B Siddiqui S Jenkins M Reisner C Martin UJ |
| author_facet | De Backer W De Backer J Vos W Verlinden I Van Holsbeke C Clukers J Hajian B Siddiqui S Jenkins M Reisner C Martin UJ |
| author_sort | De Backer W |
| collection | DOAJ |
| description | Wilfried De Backer,1 Jan De Backer,2 Wim Vos,3 Ilse Verlinden,3 Cedric Van Holsbeke,3 Johan Clukers,1 Bita Hajian,1 Shahid Siddiqui,4 Martin Jenkins,5 Colin Reisner,4,6 Ubaldo J Martin4 1Department of Respiratory Medicine, University of Antwerp, Antwerp, Belgium; 2FLUIDDA, Los Angeles, CA, USA; 3FLUIDDA, Kontich, Belgium; 4AstraZeneca, Gaithersburg, MD, USA; 5AstraZeneca, Cambridge, UK; 6Pearl – A member of the AstraZeneca Group, Morristown, NJ, USA Background: Functional respiratory imaging (FRI) uses high-resolution computed tomography (HRCT) scans to assess changes in airway volume and resistance. Patients and methods: In this randomized, double-blind, 2-week, crossover, Phase IIIB study, patients with moderate-to-severe COPD received twice-daily glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler (GFF MDI, 18/9.6 µg) and placebo MDI, formulated using innovative co-suspension delivery technology. Co-primary endpoints included the following: specific image-based airway volume (siVaw) and specific image-based airway resistance (siRaw) at Day 15, measured using FRI. Secondary and other endpoints included the following: change from baseline in post-dose forced expiratory volume in 1 second (FEV1) and inspiratory capacity (IC; spirometry) and ratio to baseline in post-dose functional residual capacity (FRC) and residual volume (RV; body plethysmography). Results: Twenty patients (46–78 years of age) were randomized and treated; of whom 19 completed the study. GFF MDI treatment increased siVaw by 75% and reduced siRaw by 71% vs placebo MDI (both P<0.0001). Image-based airway volume (iVaw) and image-based airway resistance (iRaw), without adjusting for lobe volume, demonstrated corresponding findings to the co-primary endpoint, as lobe volumes did not change with either treatment. Approximately 48% of the delivered dose of glycopyrronium and formoterol fumarate was estimated to be deposited in the lungs. Compared with placebo, GFF MDI treatment improved post-dose FEV1 and IC (443 mL and 454 mL, respectively; both P<0.001) and reduced FRC and RV (13% and 22%, respectively; both P<0.0001). There were no significant safety findings. Conclusion: GFF MDI demonstrated significant, clinically meaningful benefits on FRI-based airway volume and resistance in patients with moderate-to-severe COPD. Benefits were associated with improvements in FEV1, IC, and hyperinflation. Clinical trial registration: ClinicalTrials.gov: NCT02643082. Keywords: GFF MDI, airway volume, airway resistance, inspiratory capacity, hyperinflation, LAMA/LABA |
| first_indexed | 2024-12-19T06:05:49Z |
| format | Article |
| id | doaj.art-479dbcf80ede4418bb2145cfe493ccf2 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-19T06:05:49Z |
| publishDate | 2018-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-479dbcf80ede4418bb2145cfe493ccf22022-12-21T20:33:08ZengDove Medical PressInternational Journal of COPD1178-20052018-08-01Volume 132673268440197A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPDDe Backer WDe Backer JVos WVerlinden IVan Holsbeke CClukers JHajian BSiddiqui SJenkins MReisner CMartin UJWilfried De Backer,1 Jan De Backer,2 Wim Vos,3 Ilse Verlinden,3 Cedric Van Holsbeke,3 Johan Clukers,1 Bita Hajian,1 Shahid Siddiqui,4 Martin Jenkins,5 Colin Reisner,4,6 Ubaldo J Martin4 1Department of Respiratory Medicine, University of Antwerp, Antwerp, Belgium; 2FLUIDDA, Los Angeles, CA, USA; 3FLUIDDA, Kontich, Belgium; 4AstraZeneca, Gaithersburg, MD, USA; 5AstraZeneca, Cambridge, UK; 6Pearl – A member of the AstraZeneca Group, Morristown, NJ, USA Background: Functional respiratory imaging (FRI) uses high-resolution computed tomography (HRCT) scans to assess changes in airway volume and resistance. Patients and methods: In this randomized, double-blind, 2-week, crossover, Phase IIIB study, patients with moderate-to-severe COPD received twice-daily glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler (GFF MDI, 18/9.6 µg) and placebo MDI, formulated using innovative co-suspension delivery technology. Co-primary endpoints included the following: specific image-based airway volume (siVaw) and specific image-based airway resistance (siRaw) at Day 15, measured using FRI. Secondary and other endpoints included the following: change from baseline in post-dose forced expiratory volume in 1 second (FEV1) and inspiratory capacity (IC; spirometry) and ratio to baseline in post-dose functional residual capacity (FRC) and residual volume (RV; body plethysmography). Results: Twenty patients (46–78 years of age) were randomized and treated; of whom 19 completed the study. GFF MDI treatment increased siVaw by 75% and reduced siRaw by 71% vs placebo MDI (both P<0.0001). Image-based airway volume (iVaw) and image-based airway resistance (iRaw), without adjusting for lobe volume, demonstrated corresponding findings to the co-primary endpoint, as lobe volumes did not change with either treatment. Approximately 48% of the delivered dose of glycopyrronium and formoterol fumarate was estimated to be deposited in the lungs. Compared with placebo, GFF MDI treatment improved post-dose FEV1 and IC (443 mL and 454 mL, respectively; both P<0.001) and reduced FRC and RV (13% and 22%, respectively; both P<0.0001). There were no significant safety findings. Conclusion: GFF MDI demonstrated significant, clinically meaningful benefits on FRI-based airway volume and resistance in patients with moderate-to-severe COPD. Benefits were associated with improvements in FEV1, IC, and hyperinflation. Clinical trial registration: ClinicalTrials.gov: NCT02643082. Keywords: GFF MDI, airway volume, airway resistance, inspiratory capacity, hyperinflation, LAMA/LABAhttps://www.dovepress.com/a-randomized-study-using-functional-respiratory-imaging-to-characteriz-peer-reviewed-article-COPDGFF MDIAirway volumeAirway resistanceInspiratory capacityhyperinflationLAMA/LABA |
| spellingShingle | De Backer W De Backer J Vos W Verlinden I Van Holsbeke C Clukers J Hajian B Siddiqui S Jenkins M Reisner C Martin UJ A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD International Journal of COPD GFF MDI Airway volume Airway resistance Inspiratory capacity hyperinflation LAMA/LABA |
| title | A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD |
| title_full | A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD |
| title_fullStr | A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD |
| title_full_unstemmed | A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD |
| title_short | A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD |
| title_sort | randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate formoterol fumarate delivered by a metered dose inhaler using co suspension delivery technology in patients with copd |
| topic | GFF MDI Airway volume Airway resistance Inspiratory capacity hyperinflation LAMA/LABA |
| url | https://www.dovepress.com/a-randomized-study-using-functional-respiratory-imaging-to-characteriz-peer-reviewed-article-COPD |
| work_keys_str_mv | AT debackerw arandomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT debackerj arandomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT vosw arandomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT verlindeni arandomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT vanholsbekec arandomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT clukersj arandomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT hajianb arandomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT siddiquis arandomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT jenkinsm arandomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT reisnerc arandomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT martinuj arandomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT debackerw randomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT debackerj randomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT vosw randomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT verlindeni randomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT vanholsbekec randomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT clukersj randomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT hajianb randomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT siddiquis randomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT jenkinsm randomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT reisnerc randomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd AT martinuj randomizedstudyusingfunctionalrespiratoryimagingtocharacterizebronchodilatoreffectsofglycopyrrolateformoterolfumaratedeliveredbyametereddoseinhalerusingcosuspensiondeliverytechnologyinpatientswithcopd |